QDIS Blog

A blog about chemistry, drug development, science, and technology

Pages (999999): [1] 2 3 » ... Last »

October 16, 2006

More Mergers with Pfizer Snatching Up Powdermed

by @ 11:50 am.  Filed under Pharma News

Pfizer is acquiring Powdermed for their new technology related to vaccines.

RED HERRING | Pfizer Nabs Startup PowderMed:

Pfizer wants the technology they have developed to produce vaccines using DNA-caoted microscopic gold particles that can be placed under the skin without a needle using a pressurized gas. Powdermed is developing vaccines for herpes, chronic hepatitis and genital warts.

This is a good acquisition for Pfizer since they don’t have a presence in vaccines and the hope seems to be that this technology will be far ahead of the old egg-based vaccine or the newer developments with cell-based vaccine production.

Technorati Tags: , , ,

Email Ed Vawter



Related Posts:
  • Pfizer To Acquire BioRexis
  • Pfizer to buy Embrex for $155 million
  • Sources of Pharmaceutical Mergers Online
  • Pfizer to Cut 2,200 Marketing Jobs
  • Mergers & Acquisitions and Deals

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    Genentech Caps Cost of Cancer Drug for Some

    by @ 9:54 am.  Filed under Health News, Pharma News

    Genentech has one of the most expensive drugs for cancer in Avastatin which can cost $50,000 per year. for colon cancer. Avastin was recently approved for lung cancer but since twice as much is needed to treat lung cancer, it would cost $100,00 per year. So it was interesting to see that Genentech is capping the cost.

    Genentech Caps Cost of Cancer Drug for Some Patients - New York Times:

    The drug was to be capped at $55,000 for families of certain income levels. This isn’t too big of a deal though because many patients never live long enough to reach this cap (median survival is 12.3 months). As it is apporved for more indications based on future trials, this could change especially if

    Their other choice would have been to reduce the price of the drug across the board but it is likely this wold have reduced the income from Avastin more than just capping the cost. From the terms of maximizing their profits, this may be a good deal. Also, as Avastin is approved for additional indications, the potential for Avastin is enormous; some consider it to be able to reach$ 4 to $10 billion in sales per year.

    Technorati Tags: , , , ,

    Email Ed Vawter



    Related Posts:
  • Gardasil Not Readily Available?
  • GlaxoSmithKline Goes Head-To-Head With Merck on Cervical Cancer Vaccine
  • Prescription Drugs and OTC Products
  • FTC asks for more info on Genentech, Tanox merger
  • Genentech and Seattle Genetics Announce Agreement for SGN-40

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    Pages (999999): [1] 2 3 » ... Last »

    [powered by WordPress.]

    QDIS: blogging about chemistry, drug development, science and technology.

    Internal Links

    Categories

    Search This Blog

    Archives

    October 2006
    S M T W T F S
    « Sep   Nov »
    1234567
    891011121314
    15161718192021
    22232425262728
    293031  

    Search Entire Site

    Subscribe (It's Free!)

    Performancing

    Chemistry, science, and technology for the future.

    logo2

    General Links

    Blog Links

    Chemistry Journal Feeds

    Chemistry Feeds

    41 queries. 1.797 seconds